GHRP-6 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: GHRP-6 pharmacokinetics and endocrine effects

Growth Signal Research peptide Lyophilized verified

Also known as: GHRP6

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

2 mg, 5 mg, 10 mg

Calculator

Preset available

Storage

Lyophilized: store at -20 deg C. After reconstitution: refrigerate 2-8 deg C; verify beyond-use timing against source COA.

Solubility

Salt and supplier formulation dependent

Catalog Description

GHRP-6 was one of the earliest synthetic GH secretagogues developed, acting as a GHS-R1a (ghrelin receptor) agonist. Among the GHRP-class compounds it is associated with the strongest appetite-stimulating effect, alongside GH release; it shares the class's off-target potential for mild ACTH/cortisol co-stimulation, though less studied head-to-head than GHRP-2/hexarelin in the comparative literature.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Distribution 7.6 +/- 1.9 minutes and elimination 2.5 +/- 1.1 hours after IV dosing in nine healthy men

Onset

Acute GH response occurs within hours

Administration Routes (Research)

IV in PK and endocrine studiesIntranasal oral and sublingual studied experimentallySC use is unapproved community practice

Reported Research Effects

GH release via ghrelin-receptor agonism
Strongest appetite stimulation among the GHRP class

Reported Research Side Effects

Appetite stimulation
ACTH and cortisol increases
Glucose and insulin changes in specific experimental settings
Long-term safety is unknown

Data source: Human pharmacokinetic and endocrine challenge studies

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

1 mcg/kg as an acute endocrine challenge [IV; Single-dose human studies; Once]Source: PMID 8435889
100-400 mcg/kg as single PK doses [IV; Phase 1 single-dose study; Once]Source: PMID 23099431

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Other GH secretagogues
Active malignancy or conditions where increased GH or IGF-1 signaling is undesirable

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Five duplicated 100-300 mcg SC schedules were removed. The human PK study used much larger weight-based IV research doses and must not be converted into a self-use schedule.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

GHRP-6 human pharmacokinetics — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/23099431/

GHRP-6 endocrine challenge study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/8435889/

Route and sleep endocrine study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/10336729/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.